Table 6.
Osteoclastogenesis
| Active components | Biomaterials | Experimental model | Efficacy | References |
|---|---|---|---|---|
| Icariin | CPC | rBMSC, 20 µM; OVX rat calvarial defect model | Down-regulating RANKL | [143] |
| Icaritin | PLGA/TCP | BMSC, BMC 0.052: 100 (powder weight to solution volume); rat calvarial defect model | Down-regulating RANKL/OPG | [145] |
| Quercetin | Ti | RAW264.7, 1 mM; rabbit tibia model | Down-regulating Trap, CalcR, Ctsk, H+ATPase, MMP-9 and RANKL | [151] |
| Ursolic acid | Ti particle | RAW264.7, BMMs, 5 µM; mouse calvarial bone defect model | Down-regulating NFATc1, NF-kB and JNK signaling | [152] |
| Epigallocatechin | Ti-6Al-4 V | hADSCs, Raw264.7, 0.1, 0.5, 1 mg/mL; rabbit tibias defect model | Down-regulating TRAP, CTSK, and RAW264.7 number | [112] |
| PLLA | ADSCs, Raw 264.7, 1 mg/mL; mouse calvarial defect | Down-regulating RAW264.7 number | [113] |